Assessment of serum levels of anti‑cyclic citrullinated peptide antibodies in patients with psoriatic arthritis: A cross‑sectional study in a Brazilian cohort

Gruber,Cristiane; Skare,Thelma; Campos,Ana Paula B.; Simioni,Juliana; Maestri,Vinicius; Nisihara,Renato

doi:10.3892/br.2020.1343

Assessment of serum levels of anti‑cyclic citrullinated peptide antibodies in patients with psoriatic arthritis: A cross‑sectional study in a Brazilian cohort

Authors:
- Cristiane Gruber
- Thelma Skare
- Ana Paula B. Campos
- Juliana Simioni
- Vinicius Maestri
- Renato Nisihara
View Affiliations

Affiliations: Rheumatology Service, Mackenzie Evangelical School of Medicine Paraná, Curitiba, Paraná 80730‑300, Brazil, Medicine Department, Mackenzie Evangelical School of Medicine Paraná, Curitiba, Paraná 80730‑300, Brazil
Published online on: August 10, 2020 https://doi.org/10.3892/br.2020.1343
Article Number: 36

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Presence of the anti‑cyclic citrullinated peptide (CCP) antibody is considered a hallmark of rheumatoid arthritis, and may be found in patients with other rheumatic diseases, including psoriatic arthritis (PsA). The aim of the present study was to determine whether the anti‑CCP antibody was present in patients with psoriasis with and without arthritis. and to determine whether its presence was associated with clinical, serological and treatment data in patients with PsA. The present study was a cross‑sectional study, which included 91 patients with psoriasis (41 with arthritis and 48 without arthritis) as well as an age and sex matched control group consisting of 100 healthy individuals. Presence of the anti‑CCP antibody was determined using commercially available ELISA kits. Data on clinical, serological and treatment characteristics was obtained from reviewing each patient's medical history. The quality of life and articular inflammatory activity were assessed using the Short Form Health Survey‑12 questionnaire. Skin disease was evaluated using the Psoriasis Area Severity Index and body surface area. In the control group, 1% of individuals were positive for the anti‑CCP antibody, whereas 17.5% of the psoriasis patients were positive (P<0.001). In the patients with PsA, 20.9% were positive for the antibody, and in patients with psoriasis without joint disease, 14.5% were positive (P=0.58). Patients with polyarticular forms of PsA were more likely to be anti‑CCP positive compared with patients with skin disease without arthritis (P=0.009). In the group of patients with PsA, those who were anti‑CCP positive were more likely to suffer from polyarticular forms of arthritis, but no differences were found in the quality of life, joint disease activity, degree of skin involvement and treatment requirements (all P>0.05). In conclusion, 17.5% of patients with psoriasis and 20.9% of patients with PsA were positive for anti‑CCP antibodies. Polyarticular arthritis was more common in the anti‑CCP positive patients compared with the anti‑CCP negative patients.

View Figures

View References

1	Parisi R, Symmons DP, Griffiths CE and Ashcroft DM: Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: A systematic review of incidence and prevalence. J Invest Dermatol. 133:377–385. 2013.PubMed/NCBI View Article : Google Scholar
2	Henes JC, Ziupa E, Eisfelder M, Adamczyk A, Knaudt B, Jacobs F, Lux J, Schanz S, Fierlbeck G, Spira D, et al: High prevalence of psoriatic arthritis in dermatological patients with psoriasis: A cross-sectional study. Rheumatol Int. 34:227–234. 2014.PubMed/NCBI View Article : Google Scholar
3	Tey HL, Ee HL, Tan AS, Theng TS, Wong SN and Khoo SW: Risk factors associated with having psoriatic arthritis in patients with cutaneous psoriasis. J Dermatol. 37:426–430. 2010.PubMed/NCBI View Article : Google Scholar
4	Raposo I and Torres T: Nail psoriasis as a predictor of the development of psoriatic arthritis. Actas Dermosifiliogr. 106:452–457. 2015.PubMed/NCBI View Article : Google Scholar
5	Rouzaud M, Sevrain M, Villani AP, Barnetche T, Paul C, Richard MA, Jullien D, Misery L, Le Maître M, Aractingi S, et al: Is there a psoriasis skin phenotype associated with psoriatic arthritis? Systematic literature review. J Eur Acad Dermatol Venereol. 28 (Suppl 5):S17–S26. 2014.PubMed/NCBI View Article : Google Scholar
6	Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P and Mielants H: CASPAR Study Group: Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis Rheum. 54:2665–2673. 2006.PubMed/NCBI View Article : Google Scholar
7	Khondker L and Khan SI: Association of rheumatoid factor and uric acid with psoriatic arthritis: A review. Mymensingh Med J. 23:609–613. 2014.PubMed/NCBI
8	Kurowska W, Kuca-Warnawin EH, Radzikowska A and Maśliński W: The role of anti-citrullinated protein antibodies (ACPA) in the pathogenesis of rheumatoid arthritis. Cent Eur J Immunol. 42:390–398. 2017.PubMed/NCBI View Article : Google Scholar
9	Perez-Alamino R, Garcia-Valladares I, Cuchacovich R, Iglesias-Gamarra A and Espinoza LR: Are anti-CCP antibodies in psoriatic arthritis patients a biomarker of erosive disease? Rheumatol Int. 34:1211–1216. 2014.PubMed/NCBI View Article : Google Scholar
10	WMA declaration of Helsinki-ethical principles for medical research involving human subjects. https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/. Accessed July 17, 2020.
11	Zlatkovic-Svenda M, Kerimovic-Morina D and Stojanovic RM: Psoriatic arthritis classification criteria: Moll and wright, ESSG and CASPAR-a comparative study. Acta Reumatol Port. 38:172–178. 2013.PubMed/NCBI
12	Finlay AY: Current severe psoriasis and the rule of tens. Br J Dermatol. 152:861–867. 2005.PubMed/NCBI View Article : Google Scholar
13	Andrade TL, Camelier AA, Rosa FW, Santos MP, Jezler S and Pereira e Silva JL: Applicability of the 12-item short-form health survey in patients with progressive systemic sclerosis. J Bras Pneumol. 33:414–422. 2007.(In English, Portuguese). PubMed/NCBI View Article : Google Scholar
14	Lukas C, Landewé R, Sieper J, Dougados M, Davis J, Braun J, van der Linden S and van der Heijde D: Assessment of SpondyloArthritis international Society. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis. 68:18–24. 2009.PubMed/NCBI View Article : Google Scholar
15	Assesment of Spondyloarthritis International Society: ASDAS calculator. https://www.asas-group.org/clinical-instruments/asdas-calculator/. Accessed November 10, 2018.
16	Eker YÖ, Pamuk ÖN, Pamuk GE, Dönmez S and Çakır N: The frequency of anti-CCP antibodies in patients with rheumatoid arthritis and psoriatic arthritis and their relationship with clinical features and parameters of angiogenesis: A comparative study. Eur J Rheumatol. 1:67–71. 2014.PubMed/NCBI View Article : Google Scholar
17	Inanc N, Dalkilic E, Kamali S, Kasapoglu-Günal E, Elbir Y, Direskeneli H and Inanc M: Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis. Clin Rheumatol. 26:17–23. 2007.PubMed/NCBI View Article : Google Scholar
18	Korendowych E, Owen P, Ravindran J, Carmichael C and McHugh N: The clinical and genetic associations of anti-cyclic citrullinated peptide antibodies in psoriatic arthritis. Rheumatology (Oxford). 44:1056–1060. 2005.PubMed/NCBI View Article : Google Scholar
19	Alenius GM, Berglin E and Rantapää Dahlqvist S: Antibodies against cyclic citrullinated peptide (CCP) in psoriatic patients with or without joint inflammation. Ann Rheum Dis. 65:398–400. 2006.PubMed/NCBI View Article : Google Scholar
20	Candia L, Marquez J, Gonzalez C, Santos AM, Londoño J, Valle R, Zabaleta J, Yaqub Z and Espinoza LR: Low frequency of anticyclic citrullinated peptide antibodies in psoriatic arthritis but not in cutaneous psoriasis. J Clin Rheumatol. 12:226–229. 2006.PubMed/NCBI View Article : Google Scholar
21	Lee AN, Beck CE and Hall M: Rheumatoid factor and anti-CCP antibodies in rheumatoid arthritis: A review. Clin Lab Sci. 21:15–18. 2008.PubMed/NCBI
22	Popescu C, Zofotă S, Bojincă V and Ionescu R: Anti-cyclic citrullinated peptide antibodies in psoriatic arthritis-cross-sectional study and literature review. J Med Life. 6:376–382. 2013.PubMed/NCBI
23	Maejima H, Aki R, Watarai A, Shirai K, Hamada Y and Katsuoka K: Antibodies against cyclic citrullinated peptide in Japanese psoriatic arthritis patients. J Dermatol. 37:339–345. 2010.PubMed/NCBI View Article : Google Scholar
24	Behrens F, Koehm M, Thaçi D, Gnann H, Greger G, Maria Wittig B and Burkhardt H: Anti-citrullinated protein antibodies are linked to erosive disease in an observational study of patients with psoriatic arthritis. Rheumatology (Oxford). 55:1791–1795. 2016.PubMed/NCBI View Article : Google Scholar
25	Grover C, Kashyap B, Daulatabad D, Dhawan A and Kaur IR: Significance of anti-cyclic citrullinated peptide autoantibodies in immune-mediated inflammatory skin disorders with and without arthritis. Indian J Dermatol. 61:510–514. 2016.PubMed/NCBI View Article : Google Scholar